Take with food
Take this medicine with food.
Leaflet KYGEVVI 2g/2 g powder for oral solution
- Product code:
- W72211001
- Indicated for:
- genetically confirmed thymidine kinase 2 (TK2) deficiency with symptom onset at or before 12 years of age, in children a
- Route of administration:
- oral
- Substance:
- doxecitine + doxribtimine (pyrimidine nucleoside substrate replacement therapy)
- ATC
- A16AX29 — Alimentary tract and metabolism | Other alimentary tract and metabolism products | Other alimentary tract and metabolism products | Various alimentary tract and metabolism products
Doxecitine + doxribtimine treats children and adults with genetically confirmed thymidine kinase 2 deficiency whose symptoms began at or before 12 years of age. The disease impairs energy production in muscles. These medicines provide mitochondrial DNA precursors and may improve motor function, although their mechanism in humans is not fully confirmed.
Dissolve the powder in water and take it orally in three equal daily doses with food. A specialist calculates the dose by body weight and increases it gradually according to tolerability. Use the recommended measuring devices, not household spoons. Administration through a feeding tube requires specific instructions.
Important side effects are diarrhoea, vomiting, abdominal pain and increased liver enzymes. Digestive fluid losses can cause dehydration and electrolyte imbalance, especially in children. Liver tests are needed before treatment and during follow-up; the doctor may reduce the dose or temporarily interrupt treatment.
Contact the doctor urgently for severe diarrhoea, repeated vomiting, reduced urination, unusual sleepiness, jaundice or dark urine. Report pregnancy, breastfeeding and kidney disease. Treatment does not cure the genetic defect or replace breathing support, nutritional care and rehabilitation. Benefit is assessed through changes in strength and movement.
Dissolve the powder in water and take it orally in three equal daily doses with food. A specialist calculates the dose by body weight and increases it gradually according to tolerability. Use the recommended measuring devices, not household spoons. Administration through a feeding tube requires specific instructions.
Important side effects are diarrhoea, vomiting, abdominal pain and increased liver enzymes. Digestive fluid losses can cause dehydration and electrolyte imbalance, especially in children. Liver tests are needed before treatment and during follow-up; the doctor may reduce the dose or temporarily interrupt treatment.
Contact the doctor urgently for severe diarrhoea, repeated vomiting, reduced urination, unusual sleepiness, jaundice or dark urine. Report pregnancy, breastfeeding and kidney disease. Treatment does not cure the genetic defect or replace breathing support, nutritional care and rehabilitation. Benefit is assessed through changes in strength and movement.
General data about KYGEVVI 2g/2 g
- Substance:
- doxecitine + doxribtimine
- Product code:
- W72211001
- Concentration:
- 2g / 2g
- Pharmaceutical form:
- powder for oral solution
- Product type:
- Generic medicine
- Prescription status:
- S — Medicines dispensed with a restricted medical prescription, reserved for use in certain specialized fields.
Precautions:
General warning
Read the package leaflet before use.
Colitis / severe diarrhea
Seek medical advice if severe or persistent diarrhea occurs.
Hepatotoxicity
This medicine may affect the liver.
Additional monitoring
This medicine is subject to additional monitoring.
Requires periodic laboratory tests
Periodic laboratory tests may be required during treatment.
Breastfeeding warning
Use during breastfeeding only on medical advice.
Pregnancy warning
Use during pregnancy only on medical advice.
Pediatric warning
Use in children only as recommended in the leaflet or by a doctor.
Electrolyte disturbances
This medicine may change blood electrolyte levels.